Alport Syndrome Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Enyo Pharma, Calliditas Therapeutics, Travere Therapeutics, Inc.

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Alport Syndrome pipeline constitutes 8+ key companies continuously working towards developing 10+ Alport Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

The Alport Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Alport Syndrome Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alport Syndrome Market.

 

Some of the key takeaways from the Alport Syndrome Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Alport Syndrome treatment therapies with a considerable amount of success over the years. 

  • Alport Syndrome companies working in the treatment market are Enyo Pharma, Calliditas Therapeutics, River 3 Renal Corp., Travere Therapeutics, Inc., Chinook Therapeutics, Inc., Eloxx Pharmaceuticals, Novartis, Bayer, Evotec, and others, are developing therapies for the Alport Syndrome treatment 

  • Emerging Alport Syndrome therapies in the different phases of clinical trials are- Vonafexor, Setanaxib, R3R01, Sparsentan, Atrasentan, ELX-02, and others are expected to have a significant impact on the Alport Syndrome market in the coming years.   

  • In January 2024, ENYO Pharma (“ENYO”) has announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its Investigational New Drug (IND) application, allowing the company to begin a Phase 2 clinical trial of Vonafexor, a highly selective FXR agonist, aimed at treating Alport Syndrome.

 

Alport Syndrome Overview

Alport Syndrome is a genetic disorder that affects the kidneys, ears, and eyes. It is caused by mutations in the genes responsible for producing collagen, a protein crucial for the structure of tissues. The syndrome leads to progressive kidney disease, hearing loss, and eye abnormalities. In severe cases, it can result in end-stage kidney failure. Alport Syndrome primarily affects males, though females can also experience symptoms, typically milder. Diagnosis is confirmed through genetic testing, and treatment focuses on managing symptoms, delaying kidney damage, and improving quality of life through medications and, in some cases, kidney transplantation.

 

Get a Free Sample PDF Report to know more about Alport Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/alport-syndrome-pipeline-insight

 

Emerging Alport Syndrome Drugs Under Different Phases of Clinical Development Include:

  • Vonafexor: Enyo Pharma

  • Setanaxib: Calliditas Therapeutics

  • R3R01: River 3 Renal Corp.

  • Sparsentan: Travere Therapeutics, Inc.

  • Atrasentan: Chinook Therapeutics, Inc.

  • ELX-02: Eloxx Pharmaceuticals

 

Alport Syndrome Route of Administration

Alport Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Alport Syndrome Molecule Type

Alport Syndrome Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy 

 

Alport Syndrome Pipeline Therapeutics Assessment

  • Alport Syndrome Assessment by Product Type

  • Alport Syndrome By Stage and Product Type

  • Alport Syndrome Assessment by Route of Administration

  • Alport Syndrome By Stage and Route of Administration

  • Alport Syndrome Assessment by Molecule Type

  • Alport Syndrome by Stage and Molecule Type

 

DelveInsight’s Alport Syndrome Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Alport Syndrome product details are provided in the report. Download the Alport Syndrome pipeline report to learn more about the emerging Alport Syndrome therapies

 

Some of the key companies in the Alport Syndrome Therapeutics Market include:

Key companies developing therapies for Alport Syndrome are – Invitae Corporation, Illumina Inc, Natera Inc, PerkinElmer Inc, Quest Diagnostics Incorporated, Centogene N.V., Eurofins Discovery, Hoffmann-La Roche Ltd., Eurofins LifeCodexx GmbH, Ravgen, AstraZeneca, Lilly, Mylan N.V., Sanofi, Teva Pharmaceutical Industries Ltd., and others.

 

Alport Syndrome Pipeline Analysis:

The Alport Syndrome pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Alport Syndrome with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alport Syndrome Treatment.

  • Alport Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Alport Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alport Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Alport Syndrome drugs and therapies

 

Alport Syndrome Pipeline Market Drivers

  • Increasing Research and Development, Technological Advancements, Rising Awareness, FDA and Regulatory Approvals, Collaborations and Partnerships, are some of the important factors that are fueling the Alport Syndrome Market.

 

Alport Syndrome Pipeline Market Barriers

  • However, Limited Patient Population, High Development Costs, High Development Costs, Lack of Awareness, Clinical Trial Challenges, and other factors are creating obstacles in the Alport Syndrome Market growth.

 

Scope of Alport Syndrome Pipeline Drug Insight    

  • Coverage: Global

  • Key Alport Syndrome Companies: Enyo Pharma, Calliditas Therapeutics, River 3 Renal Corp., Travere Therapeutics, Inc., Chinook Therapeutics, Inc., Eloxx Pharmaceuticals, Novartis, Bayer, Evotec, and others

  • Key Alport Syndrome Therapies: Vonafexor, Setanaxib, R3R01, Sparsentan, Atrasentan, ELX-02, and others

  • Alport Syndrome Therapeutic Assessment: Alport Syndrome current marketed and Alport Syndrome emerging therapies

  • Alport Syndrome Market Dynamics: Alport Syndrome market drivers and Alport Syndrome market barriers 

 

Request for Sample PDF Report for Alport Syndrome Pipeline Assessment and clinical trials

 

Table of Contents

1. Alport Syndrome Report Introduction

2. Alport Syndrome Executive Summary

3. Alport Syndrome Overview

4. Alport Syndrome- Analytical Perspective In-depth Commercial Assessment

5. Alport Syndrome Pipeline Therapeutics

6. Alport Syndrome Late Stage Products (Phase II/III)

7. Alport Syndrome Mid Stage Products (Phase II)

8. Alport Syndrome Early Stage Products (Phase I)

9. Alport Syndrome Preclinical Stage Products

10. Alport Syndrome Therapeutics Assessment

11. Alport Syndrome Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Alport Syndrome Key Companies

14. Alport Syndrome Key Products

15. Alport Syndrome Unmet Needs

16 . Alport Syndrome Market Drivers and Barriers

17. Alport Syndrome Future Perspectives and Conclusion

18. Alport Syndrome Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alport Syndrome Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Enyo Pharma, Calliditas Therapeutics, Travere Therapeutics, Inc.